抗菌藥市場分析：2008年至2013年

Abstract

This brand new market analysis by visiongain examines the prospects for antibacterial drugs from 2008-2013, including sales forecasts for leading pharmaceutical products. The antibacterial market is large in terms of disease area as well as the different drug classes used to treat these infections. However, this market is entering into a crucial period with many key products losing patent protection, facing heavy generic competition. In the light of this, including other factors, visiongain predicts this market to decline in revenues - but which products will suffer most? How can you fight this generic competition? The antibacterial drug market generated revenues of $30274m in 2006 - but what will it be in 2013? Only this brand new report will tell you.

The antibacterial market only contained one blockbuster drug in 2006, this being Johnson & Johnson' s Levaquin. Visiongain predicts that there will be room for one more blockbuster drug as Levaquin will lose patent protection. This detailed report also highlights pipeline developments and important contemporary issues, especially commercial drivers and restraints.

This report will specifically analyse the world markets for the following classes of antibacterials:

• Cephalosporins
• Macrolides
• Penicillins
• Fluoroquinolones
• Carbapenems
• Miscellaneous.

The group ' miscellaneous' is an assorted group of antibacterials which includes the minor classes: the tetracyclines, aminoglycosides, glycopeptides and sulphonamides plus individual antibacterials such as Zyvox and Vancocin.

The Antibacterial Drug Market Analysis 2008 examines the market critically through a comprehensive review of available information. Sources include industrial databases, commercial news, published reports, economic research and consultation with experts. Visiongain applies financial forecasting, qualitative analyses and the assessment of unmet needs to provide a comprehensive market report with detailed analysis and informed opinion.

In particular, The Antibacterial Drug Market concentrates on the following essential aspects of the market:

• Discussion of the current pharmaceutical market
• Forecast of the worldwide pharmaceutical market from 2008-2013
• Drivers and restraints facing the antibacterial drug market
• Opportunities and threats facing the antibacterial drug market
• Growth of the antibacterial drugs market between 2008-2013
• Commercial prospects for the market-leading drugs, with sales forecasts from 2008-2013
• Individual forecasts of the leading drug classes from 2008-2013
• The potential of generics manufacturers to penetrate this market
• Pipeline developments with blockbuster potential
• Currently marketed drugs with blockbuster potential
• Discussion of unmet therapeutic needs and relative advantages of products

Why you should buy this report:

• To receive a comprehensive analysis of the prospects for antibacterial drugs from 2008-2013
• To discover predicted revenues, growth rates and other key metrics for leading pharmaceutical treatments from 2008-2013
• To determine key activities of leading companies
• To discover "hot" pipeline developments and up-and-coming products
• To determine the forces that influence the market for antibacterial drugs:
• Competitive characteristics of the market
• Drivers
• Restraints
• Strengths, weaknesses, opportunities and threats (SWOT analysis)
• To find out where the market is heading - both technologically and commercially

Table of Contents

Chapter 1 Executive Summary

• 1.1 Market Review: Growth to 2013 Will Be Low
• 1.2 Cephalosporin' s Class Leads the Market
• 1.3 Aims, Scope and Format of the Report

Chapter 2 Introduction to Bacterial Infections

• 2.1 Bacteria: An Introduction
  • 2.1.1 Bacteria Classification
  • 2.1.2 What is Bacterial Infection?
  • 2.1.3 Bacterial Invasiveness
  • 2.1.4 Bacterial Toxigenicity
  • 2.1.5 Bacterial Virulence
  • 2.1.6 The Factors that Govern the Transmission of Bacterial Disease
  • 2.1.7 Clinically Important Bacteria
• 2.2 Bacterial Disease Statistics
  • 2.2.1 Infectious Diseases - Major Cause of Deaths Worldwide
  • 2.2.2 Risk Factors for Bacterial Infections
  • 2.2.3 Re-emergence of Infectious Diseases - A Major Global Threat
• 2.3 Definition of Antibacterials
• 2.4 The History of Antibacterials
  • 2.4.1 The Discovery of Penicillin
  • 2.4.2 Early Use of Penicillin
  • 2.4.3 Penicillin Resistance
  • 2.4.4 Discovery of Streptomycin, Chloramphenicol & Tetracycline
  • 2.4.5 Antibacterial Effects
• 2.5 The Leading Antibacterials
• 2.6 The Principal Mechanisms of Action of Antibacterials
  • 2.6.1 Antibacterials as Cell Wall Synthesis Inhibitors
  • 2.6.2 Antibacterials as Cell Membrane Inhibitors
  • 2.6.3 Antibacterials as Protein Synthesis Inhibitors
  • 2.6.4 The Effects of Antibacterials on Nucleic Acids
• 2.7 Antibiotics as Competitive Inhibitors
• 2.8 Antibacterial Classification by Chemical Structure
  • 2.8.1 Penicillin
  • 2.8.2 Semisynthetic Penicillins
  • 2.8.3 Carbapenems
  • 2.8.4 Cephalosporins
  • 2.8.5 Quinolones and Fluoroquinolones
  • 2.8.6 Tetracyclines
  • 2.8.7 Aminoglycosides
  • 2.8.8 Sulphonamides
  • 2.8.9 Macrolides
  • 2.8.10 Glycopeptides
  • 2.8.11 Oxazolidinones
• 2.9 Broad-Spectrum vs Narrow-Spectrum Antibiotics

Chapter 3 The World Market for Antibacterials 2008-2013

• 3.1 The Global Antibacterial Drug Market Will Decline During 2008-2013
• 3.2 Pfizer Currently Leads the Antibacterials Market
• 3.3 Cephalosporins to Continue Their Domination of the Antibacterials Market Despite Negative Growth
• 3.4 Miscellaneous Class Will Display High Revenues During 2006-2013
• 3.5 Levaquin is Currently the World' s Leading Antibacterial Agent - But will it Last?
• 3.6 Patent Expiry Will Reduce Growth Rates
• 3.7 Prescriptions for Antibiotics in the Developed World Are Falling
• 3.8 Pharmaceutical Companies Accept that Future Antibacterial Blockbuster Drugs Will Be Increasingly Rare
• 3.9 Generic Drugs Are Not Necessarily Cheap
• 3.10 Competition in the Antibacterials Drug Market to Become Increasingly Intense

Chapter 4 The World Market for Cephalosporins, 2008-2013

• 4.1 Cephalosporins Will Suffer From Patent Expiration
• 4.2 Abbott' s Omnicef Currently Leads the Cephalosporins Market
  • 4.2.1 Omnicef Will Lose Dominance in This Class to Maxipime
• 4.3 Rocephin Will Decline in Growth
  • 4.3.1 Rocephin Already Suffers From Generic Competition
• 4.4 Maxipime Sales Will be Affected by the Loss of Patent Protection

Chapter 5 The World Market for Fluoroquinolones, 2008-2013

• 5.1 Increased Competition Will Lower Revenues Among the Fluoroquinolones
• 5.2 Fluoroquinolones Linked With Side Effects
• 5.3 Will J&J' s Levaquin Still Dominate the Fluoroquinolones Market After Patent Expiration?
  • 5.3.1 Levaquin Faces Generic Competition
  • 5.3.2 Levaquin Approved for Urinary Tract Infections and Acute Pyelonephritis
• 5.4 Avelox Will Exhibit Steady Growth
  • 5.4.1 Head-to-Head Study Finds Avelox to be More Effective in Patients with CAP
  • 5.4.2 Avelox Monotherapy as Effective as Combination Therapy in Patients With Severe CAP
  • 5.4.3 Avelox Monotherapy as Effective as Multi-Dose Combination Therapy in Patients With cIAI
  • 5.4.4 Bayer Warns Doctors on Rare Avelox Side Effects
• 5.5 Ciproxin Will Decline in Growth
• 5.6 Cravit Will Gradually Decline in Sales

Chapter 6 The World Market for Broad Spectrum Penicillins, 2008-2013

• 6.1 Penicillins Will Retain Their Niche Despite a Marked Decline in Sales
• 6.2 Can GSK' s Augmentin Overcome Generic Competition?
  • 6.2.1 Why Will Augmentin' s Revenue Drop?
• 6.3 Tazocin Will Decline in Sales

Chapter 7 The World Market for Macrolides, 2008-2013

• 7.1 The Macrolides Will Face Decreased Growth
  • 7.1.1 Macrolides: Possible Extra-Infectious Indications May Expand the Market
  • 7.1.2 The Immunomodulatory Effects of Macrolides May Aid Revenue Growth
  • 7.1.3 Macrolides May Have a Clinical use in Other Chronic Lower Airway Diseases
• 7.2 Abbott' s Klacid/Biaxin Leads This Market
  • 7.2.1 Klacid/Biaxin Suffers From Generic Competition
• 7.3 Zithromax Faces Negative Growth
  • 7.3.1 Pfizer Petitions FDA to Recall Generic Azithromycin Products to Correct Misbranding
• 7.4 Can Azithromycin PFIZ Recover Revenues Lost From Zithromax?

Chapter 8 The World Market for Carbapenems. 2008-2012

• 8.1 Carbapenems Will See High Growth
• 8.2 Merck & Co' s Zienam Leads This Market
• 8.3 Merrem Exhibits Strong Growth
  • 8.3.1 Merrem Receives FDA Approval for Complicated Skin Infections

Chapter 9 The World Market for Miscellaneous Antibacterials, 2008-2013

• 9.1 Miscellaneous Antibacterials Will See High Growth as Sales Increases
• 9.2 Pfizer' s Zyvox Set to Reach Blockbuster Status
  • 9.2.1 Zyvox Will Overtake Levaquin to Become the New Market Leader in the Antibacterials Sector
• 9.3 Targocid Shows Some Positive Growth - But Will it Continue?
• 9.4 Vancocin Will Exhibit Negative Growth

Chapter 10 An Analysis of Factors That Influence the Antibacterials Market

• 10.1 SWOT Analysis of the Antibacterials Market
• 10.2 Drivers and Restraints on Market Growth
  • 10.2.1 Market Drivers
  • 10.2.2 Market Restraints
• 10.3 To What Extent is the Antibacterials Market Threatened by Generic Substitutes?
  • 10.3.1 The Threat of Generic Drugs to Brand Name Pharmaceuticals
• 10.4 Lifecycle Management Strategies Will Become More Prominent to Protect Soon-to-be off-Patent Drugs
• 10.5 Additional Indications for Currently Available Brands May be an Advantage
• 10.6 Antibacterial Resistance Is Due to Increased Infection Rates and Antibacterial Overuse
  • 10.6.1 Concerns Over Antibacterial Use
  • 10.6.2 FDA Measures on Bacterial Resistance
  • 10.6.3 Tackling Antibacterial Resistance
  • 10.6.4 The Use of Narrow Spectrum Antibacterials is the Best Strategy to Avoid Resistance
  • 10.6.5 Antibiotics in the US Carry Warnings Against Overuse
• 10.7 Comparative Studies - A Two Edged Sword
• 10.8 Challenges that Face Antibacterials Pharmaceutical Developers
• 10.9 Future Antibacterial Blockbuster Drugs is Increasingly Unlikely
• 10.10 Antibacterials in the Developing Countries
• 10.11 The Future of the Antibacterials Market - Closing Comments

Chapter 11 Antibacterials Pipeline Products

• 11.1 Summary of Antibacterials Pipeline Products From Phase II and Above
• 11.2 The Antibacterials Pipeline is Large
• 11.3 The Potential of the Antibacterials Market Has Encouraged R&D
• 11.4 Innovation Rules For Early Stage Pipeline Drugs
• 11.5 The FDA Will Fast Track New Antibacterials
• 11.6 Traditional Antibacterial Drugs are Less Popular
• 11.7 Promising Pipeline Drugs - Overview
  • 11.7.1 Middlebrook' s Moxatag
  • 11.7.2 Shogoo' s SPK 0602
  • 11.7.3 Pfizer' s Zeven (dalbavancin)
  • 11.7.4 Arpida' s Iclaprim
  • 11.7.5 Targanta' s Oritavancin
• 11.8 Gracevit Gets Approval for Manufacturing and Marketing
• 11.9 New Approaches to Antibacterial Drug Development
• 11.10 Antibacterial Pipeline Shows Short- and Long-Term Potential

Chapter 12 Conclusion

• 12.1 Patent Expiry of Brand Name Products Will Reduce Growth Rates
• 12.2 Cephalosporins to Continue Their Domination of the Antibacterials Market Despite Negative Growth
• 12.3 Future Antibacterial Blockbuster Drugs are Increasingly Unlikely
• 12.4 Market Drivers
• 12.5 Market Restraints
• 12.6 Opportunities in the Antibacterials Market
• 12.7 Antibacterials Pipeline Overview
• 12.8 The Future of the Antibacterials Market - Closing Comments

List of Tables

• Table 1.1 Top Ten Leading Antibacterials, by Revenues ($m), 2006
• Table 2.1 Clinically Important Bacteria
• Table 2.2 The Leading Antibacterials by Class, 2006
• Table 2.3 Antibiotic Action by Drug Class
• Table 3.1 World Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013, 2018 & 2023
• Table 3.2 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Antibacterial Drugs by Class, 2006 & 2013
• Table 3.3 The Leading Top Ten Antibacterials, 2006
• Table 4.1 World Revenues ($m) for Cephalosporin Drugs, 2008-2013, 2018 & 2023
• Table 4.2 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Cephalosporin Drugs, 2006 & 2013
• Table 5.1 World Revenues ($m) for Fluoroquinolones, 2008-2013, 2018 & 2023
• Table 5.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Fluoroquinolones, 2006 & 2013
• Table 6.1 World Revenues ($m) for Penicillins by Leading Products, 2008-2013, 2018 & 2023
• Table 6.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Penicillins, 2006 & 2013
• Table 7.1 World Revenues ($m) for Macrolides, 2008-2013, 2018 & 2023
• Table 7.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Macrolides, 2006 & 2013
• Table 8.1 World Revenues ($m) for Carbapenems, 2008-2013, 2018 & 2023
• Table 8.2 World Market Revenue ($m) and Market Share (%) and 7-Year CAGR (%) for Carbapenems, 2006 & 2013
• Table 9.1 World Revenues ($m) for Miscellaneous Drugs, 2008-2013, 2018 & 2023
• Table 9.2 World Market Revenue ($m), 7-Year CAGR (%) and Market Share (%) for Miscellaneous Drugs, by Class, 2006 & 2013
• Table 10.1 A SWOT Chart for the Antibacterials Market, 2008-2013
• Table 11.1 Pipeline Drugs for Antibacterials, 2008
• Table 12.1 World Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013, 2018 & 2023
• Table 12.2 Top Ten Antibacterial Drugs, by Revenue ($m), 2006

List of Figures

• Figure 3.1 Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013
• Figure 3.2 Total Revenues ($m) for the Antibacterial Drugs Market, 2008-2013
• Figure 3.3 World Market Share (%) for Antibacterial Drugs by Class, 2006
• Figure 3.4 World Market Share (%) for Antibacterial Drugs by Class, 2013
• Figure 3.5 The Leading Top Ten Antibacterials by Revenue ($m), 2006
• Figure 4.1 Total World Revenues ($m) for Cephalosporin Drugs, 2008-2013
• Figure 4.2 World Revenues ($m) for the Cephalosporin Drugs by Leading Product, 2008-2013
• Figure 4.3 World Market Share (%) for Cephalosporin Drugs by Leading Product, 2006
• Figure 4.4 World Market Share (%) for Cephalosporin Drugs by Leading Product, 2013
• Figure 4.5 World Omnicef Revenues ($m), 2008-2013
• Figure 4.6 World Rocephin Revenues ($m), 2008-2013
• Figure 4.7 World Maxipime Revenues ($m), 2008-2013
• Figure 5.1 Total World Revenues ($m) for Fluoroquinolones, 2008-2013
• Figure 5.2 World Revenues ($m) for the Fluoroquinolones by Leading Products, 2008-2013
• Figure 5.3 World Market Share (%) for Fluoroquinolones by Products, 2006
• Figure 5.4 World Market Share (%) for Fluoroquinolones by Products, 2013
• Figure 5.5 World Levaquin Revenues ($m), 2008-2013
• Figure 5.6 World Avelox Revenues ($m), 2008-2013
• Figure 5.7 World Ciproxin Revenues ($m), 2008-2013
• Figure 5.8 World Cravit Revenues ($m), 2008-2013
• Figure 6.1 Total World Revenues ($m) for Penicillins, 2008-2013
• Figure 6.2 World Revenues ($m) for the Penicillins by Leading Product, 2008-2013
• Figure 6.3 World Market Share (%) for Penicillins, 2006
• Figure 6.4 World Market Share (%) for Penicillins, 2013
• Figure 6.5 World Augmentin Revenues ($m), 2008-2013
• Figure 6.6 World Tazocin Revenues ($m), 2008-2013
• Figure 7.1 Total World Revenues ($m) for Macrolides, 2008-2013
• Figure 7.2 World Revenues ($m) for the Macrolides by Leading Product, 2008-2013
• Figure 7.3 World Market Share (%) for Macrolides, 2006
• Figure 7.4 World Market Share (%) for Macrolides, 2013
• Figure 7.5 World Klacid Revenues ($m), 2008-2013
• Figure 7.6 World Zithromax Revenues ($m), 2008-2013
• Figure 7.7 World Azithromycin PFIZ Revenues ($m), 2008-2013
• Figure 8.1 Total World Revenues ($m) for Carbapenems, 2008-2013
• Figure 8.2 World Revenues ($m) for the Carbapenems by Leading Product, 2008-2013
• Figure 8.3 World Market Share (%) for Carbapenems, 2006
• Figure 8.4 World Market Share (%) for Carbapenems, 2013
• Figure 8.5 World Zienam Revenues ($m), 2008-2013
• Figure 8.6 World Merrem Revenues ($m), 2008-2013
• Figure 9.1 Total World Revenues ($m) for Miscellaneous Drugs, 2008-2013
• Figure 9.2 World Revenues ($m) for the Miscellaneous Drugs by Leading Product, 2008-2013
• Figure 9.3 World Market Share (%) for Miscellaneous Drugs by Leading Product, 2006
• Figure 9.4 World Market Share (%) for Miscellaneous Drugs by Leading Product, 2013
• Figure 9.5 World Zyvox Revenues ($m), 2008-2013
• Figure 9.6 World Targocid Revenues ($m), 2008-2013
• Figure 9.7 World Vancocin Revenues ($m), 2008-2013
• Figure 12.1 Revenues ($m) for the Leading Antibacterial Drugs, by Class, 2008-2013

Companies Mentioned

• Abbott
• Agennix
• Arpida
• Asubio Pharma
• Basilea
• Bausch & Lomb
• Daiichi Sankyo
• Eli Lilly
• Enanta
• Flamel Technologies
• Genaera
• Genzyme
• Giaconda
• Gilead Sciences
• GSK
• Inhibitex
• InSite Vision
• Johnson & Johnson
• Leiden University
• Merck&Co
• MiddleBrook
• Migenix
• Neosil
• NovaBay
• Novartis
• Novexel
• Optimer
• Ortho-McNeil
• Otsuka
• Pathogenics
• Pfizer
• Pharming
• Photopharmica
• Procter & Gamble
• Rib-X
• Roche
• Schering-Plough
• Shogoo Pharmaceuticals
• Takeda
• Targanta
• Tekmira ; Aradigm
• Theravance
• Wakunaga
• Wockhardt
• Wyeth
• XOMA